183 related articles for article (PubMed ID: 35861630)
1. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.
Wada T; Mori-Anai K; Takahashi A; Matsui T; Inagaki M; Iida M; Maruyama K; Tsuda H
J Diabetes Investig; 2022 Dec; 13(12):1981-1989. PubMed ID: 35861630
[TBL] [Abstract][Full Text] [Related]
2. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR; McCullough PA; Buse JB; Anderson J
Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
[TBL] [Abstract][Full Text] [Related]
3. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
7. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
[TBL] [Abstract][Full Text] [Related]
8. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
10. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
11. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL
Clin J Am Soc Nephrol; 2023 Jun; 18(6):748-758. PubMed ID: 36999981
[TBL] [Abstract][Full Text] [Related]
13. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):903-914. PubMed ID: 33065060
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
18. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
Li JW; Arnott C; Heerspink HJL; MBiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ
J Am Heart Assoc; 2022 Aug; 11(16):e025045. PubMed ID: 35929472
[TBL] [Abstract][Full Text] [Related]
19. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
[TBL] [Abstract][Full Text] [Related]
20. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]